Two separate teal component forms in a grouped arrangement.

Our evidence assessments are specific to a combination, outcome, population, and formulation.

Read our grading method

Wolverine stack

BPC-157 + TB-500

What is the Wolverine stack? Examine BPC-157 with TB-500, the small human subgroup, animal combination research, safety, and unanswered dosing questions.

Peptide stack
Written by

Recorded source check: 4 October 2026

Review and updates

Overview

The Wolverine stack is a name used for BPC-157 plus TB-500.[1] The available combination research does not establish that the pair heals injuries better than either ingredient in people. A small human case series and a rat experiment answer narrower questions.[2][3] The evidence therefore needs to be read at the level of the actual intervention and measured outcome. This guide separates findings about the individual ingredients from findings about the complete combination, and keeps unresolved questions about formulation, benefit, and safety visible.

Ingredients

  • BPC-157Read the injury-recovery and safety evidence.
  • TB-500Check the distinction between thymosin beta-4 and its fragments.

The names require care. FDA identifies TB-500 as the thymosin beta-4 fragment LKKTETQ, while the knee report describes thymosin beta-4. Treating these labels as interchangeable would hide a formulation uncertainty.[2][4] Before applying a study to a product, match the exact molecule, route, population, and outcome. A product nickname is not enough to establish that match. Ingredient names identify the proposed combination, but interpreting a study also requires the chemical identity and preparation actually tested. A paper about one ingredient, a different fragment, or a different route does not automatically apply to the complete blend described on this page.

Why combine them?

The combination brings together two peptides investigated in injury-related research. The selected knee-pain report and tendon experiment provide a way to examine the pair, but a reason to study two ingredients together is different from evidence that the combination works better.[2][3] A proposed reason to combine ingredients is a research question rather than a demonstrated advantage. To support an added benefit, a study needs to compare the complete combination with relevant alternatives and measure outcomes that matter to the intended use.

Combination benefits

In the 2021 knee-pain case series, four people received BPC-157 with thymosin beta-4. Treatment was not randomized, so the subgroup cannot establish an advantage over BPC-157 alone. Pain reports also do not demonstrate structural tendon or ligament repair.[2] A 2026 experiment compared BPC-157, TB-500, their combination, and control after Achilles tendon surgery in 32 rats. The combination showed no additional benefit over the individual treatments. Only four tendons per group contributed to each type of endpoint.[3] A useful comparison would test the combination against each ingredient and an appropriate control, with predefined outcomes such as function, return to activity, and adverse events. Structural healing would need its own measurement. Until then, “synergy” is a hypothesis. Lack of demonstrated additional benefit is not proof that every possible combination is ineffective; it is a reason to keep the claim narrower than the marketing.

Safety & interactions

FDA flags BPC-157 and the TB-500 fragment for limited safety information and concerns involving immune reactions or peptide impurities.[4] The studies do not validate a commercial blend, a home-injection technique, or a long-term regimen. Discuss an injury and its treatment options with a qualified clinician.[2][3] Interpret these observations alongside the study population, route, and length of follow-up. A report of an event does not by itself establish causation, while a study that reports few events cannot exclude uncommon or delayed harms.

Read the Medical Disclaimer.

Forms & dosing

These sources do not establish a validated human dose, ratio, or cycle for injury recovery. Translating an experimental schedule into a consumer protocol would go beyond their findings.[2][3] The amount administered is only one part of an intervention: formulation, route, frequency, treatment duration, and monitoring also define what was tested. Keeping those details attached to a result prevents a research schedule from being presented as a validated regimen for a different use.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Selected findings and their main limitations. Open an outcome or source count for the complete assessment. Counts refer to cited documents, not necessarily independent studies.
Outcome, finding and study designEvidence certaintySources
Human researchUncontrolled human case series.[2]

The small, nonrandomized subgroup cannot establish an added treatment effect.[2]

Main limitation: The studied preparation cannot be assumed equivalent to a commercial TB-500 blend.[2]

Animal or cell researchControlled rat experiment.[3]

No additional benefit was demonstrated for the combination in this model.[3]

Main limitation: An early surgical rat model cannot establish clinical recovery in people.[3]

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

Scope identifies studies of this combination and studies of its individual ingredients. Ingredient studies do not establish the benefits or safety of the combination.

CombinationPDF recordEffects of BPC-157 and TB-500 on Achilles tendon healing
IngredientPDF recordAntiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy
IngredientPDF recordBPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment
IngredientPDF recordBPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats
IngredientPDF recordBypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine
IngredientPDF recordCelecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
IngredientPDF recordClopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157
IngredientPDF recordComplex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats
IngredientPDF recordCounteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine
IngredientPDF recordEffect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
IngredientPDF recordEffects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short- Bowel Rats
IngredientPDF recordEndothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery
IngredientPDF recordEsophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME
IngredientPDF recordFourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157
IngredientPDF recordImpact of pentadecapeptide BPC 157 on muscle healing
IngredientPDF recordIn relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro
IngredientPDF recordIntra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
IngredientPDF recordIntragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot
IngredientPDF recordModulatory effects of BPC 157 on vasomotor tone and the activation of Src‑Caveolin‑1‑endothelial nitric oxide synthase pathway
IngredientPDF recordNovel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy
IngredientPDF recordOccluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157
IngredientPDF recordOcclusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension
IngredientPDF recordOver-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157
IngredientPDF recordPentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine
IngredientPDF recordPentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
IngredientPDF recordPentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion
IngredientPDF recordPentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats
IngredientPDF recordPharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs
IngredientPDF recordProtective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia–Reperfusion Injury
IngredientPDF recordProtective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury
IngredientPDF recordProtective effects of pentadecapeptide BPC 157 on gastric ulcer in rats
IngredientPDF recordRobert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157
IngredientPDF recordSafety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
IngredientPDF recordSalutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
IngredientPDF recordStable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS
IngredientPDF recordStable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
IngredientPDF recordStable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights
IngredientPDF recordThe anti-nociceptive effect of BPC-157 on the incisional pain model in rats
IngredientPDF recordThe effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats
IngredientPDF recordTherapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats
IngredientPDF recordTracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System—Triple NO-Agent Approach in Rats
IngredientPDF record0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
IngredientPDF recordA first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
IngredientPDF recordAssociation of serum thymosin β4 with malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: a cross-sectional study
IngredientPDF recordEctopic Expression of Human Thymosin β4 Confers Resistance to Legionella pneumophila during Pulmonary and Systemic Infection in Mice
IngredientPDF recordExpression and localisation of thymosin beta- 4 in the developing human early fetal heart
IngredientPDF recordGlobal Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma
IngredientPDF recordHypomethylation of thymosin β4 promoter is associated with glucocorticoid therapy in patients with acute-on-chronic hepatitis B-induced liver failure
IngredientPDF recordHypoxia/reoxygenation-experienced cancer cell migration and metastasis are regulated by Rap1- and Rac1-GTPase activation via the expression of thymosin beta-4
IngredientPDF recordIdentifi cation of Thymosin β 4 as an effector of Hand1-mediated vascular development
IngredientPDF recordLocal Photorelease of Caged Thymosin β4 in Locomoting Keratocytes Causes Cell Turning
IngredientPDF recordModulation of the interaction between G-actin and thymosin β4 by the ATP/ADP ratio: Possible implication in the regulation of actin dynamics
IngredientPDF recordPEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo
IngredientPDF recordRGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
IngredientPDF recordRecombinant Human Thymosin β4 Attenuates Endotoxemia-Induced ALI and EAE by Suppressing Inflammatory and Oxidative Responses
IngredientPDF recordRecombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease
IngredientPDF recordRecombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection
IngredientPDF recordRecombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling
IngredientPDF recordRecombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis
IngredientPDF recordReparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function
IngredientPDF recordSerum thymosin β4 levels in patients with hepatitis B virusrelated liver failure
IngredientPDF recordSignificance of Thymosin β4 and Implication of PINCH-1-ILK-α-Parvin (PIP) Complex in Human Dilated Cardiomyopathy
IngredientPDF recordStructural basis of actin sequestration by thymosin-β4: implications for WH2 proteins
IngredientPDF recordSynthesis of thymosin β4 by peritoneal macrophages and adherent spleen cells
IngredientPDF recordThe Control of Actin Nucleotide Exchange by Thymosin β4 and Profilin. A Potential Regulatory Mechanism for Actin Polymerization in Cells
IngredientPDF recordThymosin β4-Enhancing Therapeutic Efficacy of Human Adipose-Derived Stem Cells in Mouse Ischemic Hindlimb Model
IngredientPDF recordThymosin β4 Is an Endogenous Iron Chelator and Molecular Switcher of Ferroptosis
IngredientPDF recordThymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice
IngredientPDF recordThymosin β4 Regulates Focal Adhesion Formation in Human Melanoma Cells and Affects Their Migration and Invasion
IngredientPDF recordThymosin β4 alleviates renal fibrosis and tubular cell apoptosis through TGF-β pathway inhibition in UUO rat models
IngredientPDF recordThymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell–derived cardiomyocytes in a porcine model of acute myocardial infarction
IngredientPDF recordThymosin β-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells
IngredientPDF recordThymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction
IngredientPDF recordThymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF- κB signaling axis in APP/PS1 mice
IngredientPDF recordThymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing
IngredientPDF recordThymosin Beta-4 Suppresses Osteoclastic Differentiation and Inflammatory Responses in Human Periodontal Ligament Cells
IngredientPDF recordThymosin-β4 Regulates Motility and Metastasis of Malignant Mouse Fibrosarcoma Cells
IngredientPDF recordThymosin β4 (Fx peptide) is a potent regulator of actin polymerization in living cells
IngredientPDF recordThymosin β4: A ubiquitous peptide in rat and mouse tissues
IngredientPDF recordThymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids
IngredientPDF recordThymosin beta‑4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells
IngredientPDF recordThymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
IngredientPDF recordThymosin β4 Sequesters the Majority of G-actin in Resting Human Polymorphonuclear Leukocytes

FAQs

Is the Wolverine stack better than BPC-157 alone?
Quick answer:

The human comparison is too small and uncontrolled to establish superiority.[2] The relevant question is whether the measured outcome matches the benefit being claimed. Changes in symptoms, laboratory measurements, and physical function answer different questions, so evidence for one should not silently become evidence for the others. The comparison must also preserve the population and outcome being discussed; a different intervention would need its own assessment.

Does a premixed vial have the same evidence?
Quick answer:

A combination label does not demonstrate that its contents match a study. Identity, route, purity, and formulation must be checked separately; an ingredient paper does not validate a finished blend. Ingredient names identify the proposed combination, but interpreting a study also requires the chemical identity and preparation actually tested. A paper about one ingredient, a different fragment, or a different route does not automatically apply to the complete blend described on this page.

How is Wolverine different from GLOW and KLOW?
Quick answer:

GLOW adds GHK-Cu to the Wolverine pair; KLOW adds KPV to that three-ingredient combination. These are naming conventions, not a ranking of effectiveness.[1] Ingredient names identify the proposed combination, but interpreting a study also requires the chemical identity and preparation actually tested. A paper about one ingredient, a different fragment, or a different route does not automatically apply to the complete blend described on this page.

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for Wolverine stack.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

4 sources
  1. GLOW vs KLOW vs Wolverine Stack: Which One? — naming reference only (2026)Commercial description · Names and ingredients only
  2. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (2021)Primary research · Human case seriesRead review · DraftSave study
  3. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (2026)Primary research · Animal experimentRead review · DraftSave study
  4. FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Accessed 2026-10-04)Regulatory assessmentSave study